CLORAZEPATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Clorazepate, and what generic alternatives are available?
Clorazepate is a drug marketed by Able, Am Therap, Dava Pharms Inc, Gd Searle Llc, Natco Pharma Usa, Purepac Pharm, Quantum Pharmics, Rising, Usl Pharma, Warner Chilcott, Watson Labs, Aurobindo Pharma, Aurolife Pharma Llc, Corepharma, Lederle, Novitium Pharma, Sun Pharm Inds Ltd, and Taro. and is included in fifty-eight NDAs.
The generic ingredient in CLORAZEPATE is clorazepate dipotassium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clorazepate
A generic version of CLORAZEPATE was approved as clorazepate dipotassium by AUROBINDO PHARMA on July 17th, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CLORAZEPATE?
- What are the global sales for CLORAZEPATE?
- What is Average Wholesale Price for CLORAZEPATE?
Summary for CLORAZEPATE
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 58 |
| Drug Prices: | Drug price information for CLORAZEPATE |
| DailyMed Link: | CLORAZEPATE at DailyMed |


